Literature DB >> 22454465

Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells.

Sarah Boudová1, Haishan Li, Mohammad M Sajadi, Robert R Redfield, C David Pauza.   

Abstract

BACKGROUND: CD4- Vγ2Vδ2 T cells are depleted during human immunodeficiency virus (HIV) infection but can recover to near normal levels in patients who spontaneously control viremia in the absence of therapy. By contrasting Vγ2Vδ2 T-cell numbers, phenotype, and T-cell receptor (TCR) repertoire, we investigate the dynamic tension between active immunity and progressive T-cell destruction during persistent viremia.
METHODS: Peripheral blood Vγ2Vδ2 T-cell levels and phenotypes were characterized by flow cytometry. Lymphoproliferation assays measured functional responses. Spectratyping characterized damage to the TCR repertoire.
RESULTS: Levels, responses to antigen and the proportion of T effector memory Vγ2Vδ2 T cells in patients with persistent viremia, were intermediate between patients with natural virus suppression (NVS) and patients receiving antiretroviral therapy. Damage to the TCR γ-2 chain repertoire and depletion of CD56+ Vγ2Vδ2 T cells were more pronounced in viremic patients, compared with antiretroviral therapy recipients and patients with natural virus suppression.
CONCLUSIONS: Characteristics of Vγ2Vδ2 T cells in viremic patients reflect both active responses (increasing cell numbers, better antigen responses, and higher proportion of effector memory cells) and ongoing damage (repertoire changes and loss of CD56+ cells). Unlike patients who control viremia to undetectable levels, Vγ2Vδ2 T cells are diminished during persistent viremia and may eventually be lost because of progressive destruction of the TCR repertoire.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454465      PMCID: PMC3324402          DOI: 10.1093/infdis/jis217

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.

Authors:  Hirohito Kobayashi; Yoshimasa Tanaka; Hiroaki Shimmura; Nagahiro Minato; Kazunari Tanabe
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

3.  Impact of age, gender, and race on circulating γδ T cells.

Authors:  Cristiana Cairo; Cheryl L Armstrong; Jean Saville Cummings; Carl O Deetz; Ming Tan; Changwan Lu; Charles E Davis; C David Pauza
Journal:  Hum Immunol       Date:  2010-06-30       Impact factor: 2.850

4.  Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway.

Authors:  R K Keller; S J Fliesler
Journal:  Biochem Biophys Res Commun       Date:  1999-12-20       Impact factor: 3.575

5.  Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.

Authors:  Fabrizio Poccia; Cristiana Gioia; Federico Martini; Alessandra Sacchi; Paola Piacentini; Massimo Tempestilli; Chiara Agrati; Alessandra Amendola; Amina Abdeddaim; Chrysoula Vlassi; Miroslav Malkovsky; Gianpiero D'Offizi
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

6.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Authors:  G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

Review 7.  New concepts in the immunopathogenesis of HIV infection.

Authors:  G Pantaleo; A S Fauci
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells.

Authors:  David J Riedel; Mohammad M Sajadi; Cheryl L Armstrong; Jean-Saville Cummings; Cristiana Cairo; Robert R Redfield; C David Pauza
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

9.  V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.

Authors:  Hirotake Tokuyama; Tomomi Hagi; Stephen R Mattarollo; Jacqueline Morley; Qiao Wang; Hang-Fai So; Hang Fai-So; Fuminori Moriyasu; Mie Nieda; Andrew J Nicol
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

10.  Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.

Authors:  Francesco Dieli; Fabrizio Poccia; Martin Lipp; Guido Sireci; Nadia Caccamo; Caterina Di Sano; Alfredo Salerno
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  14 in total

1.  Reply to Hartjen et al.

Authors:  Sarah Boudova; Haishan Li; Mohammad M Sajadi; Robert R Redfield; Cristiana Cairo; C David Pauza
Journal:  J Infect Dis       Date:  2013-04-01       Impact factor: 5.226

2.  Mucosal and Systemic γδ+ T Cells Associated with Control of Simian Immunodeficiency Virus Infection.

Authors:  Iskra Tuero; David Venzon; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2016-11-04       Impact factor: 5.422

3.  The potential role of CD16+ Vγ2Vδ2 T cell-mediated antibody-dependent cell-mediated cytotoxicity in control of HIV type 1 disease.

Authors:  Xuan He; Hua Liang; Kunxue Hong; Haishan Li; Hong Peng; Yangyang Zhao; Manxue Jia; Yuhua Ruan; Yiming Shao
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-13       Impact factor: 2.205

Review 4.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

5.  The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy.

Authors:  Suchita Chaudhry; Cristiana Cairo; Vanessa Venturi; C David Pauza
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

6.  Adoptive transfer of aminobisphonate-expanded Vγ9Vδ2+ T cells does not control HIV replication in a humanized mouse model.

Authors:  Bhawna Poonia
Journal:  Immunotherapy       Date:  2016-05       Impact factor: 4.196

7.  Distortion of memory Vδ2 γδ T cells contributes to immune dysfunction in chronic HIV infection.

Authors:  Zhen Li; Yanmei Jiao; Yu Hu; Lianxian Cui; Dexi Chen; Hao Wu; Jianmin Zhang; Wei He
Journal:  Cell Mol Immunol       Date:  2014-09-15       Impact factor: 11.530

8.  HIV infection of monocytes-derived dendritic cells inhibits Vγ9Vδ2 T cells functions.

Authors:  Alessandra Sacchi; Alessandra Rinaldi; Nicola Tumino; Rita Casetti; Chiara Agrati; Federica Turchi; Veronica Bordoni; Eleonora Cimini; Federico Martini
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 9.  γδ T Cells in HIV Disease: Past, Present, and Future.

Authors:  C David Pauza; Bhawna Poonia; Haishan Li; Cristiana Cairo; Suchita Chaudhry
Journal:  Front Immunol       Date:  2015-01-30       Impact factor: 7.561

10.  Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy.

Authors:  Bhawna Poonia; C David Pauza
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.